975-P: Comparison of Glycemic Variability, Assessed by Continuous Glucose Monitoring System (CGMS) during Early Post-Transplantation Period, between the Recipients of Kidney and Liver Transplantation

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 975-P
Author(s):  
HEUNG YONG JIN ◽  
YU JI KIM ◽  
KYUNG AE LEE ◽  
TAE SUN PARK
2014 ◽  
Vol 21 (1) ◽  
pp. 47-54 ◽  
Author(s):  
Simona Popa ◽  
Cristina Văduva ◽  
Maria Moţa ◽  
Eugen Moţa

Abstract Background and Aims. Peritoneal dialysis (PD) is accompanied by a multitude of factors that influence glycemic variability, and HbA1c does not detect dynamic glucose changes. In this study we wanted to assess glycemic variability, using a 72-hour continuous glucose monitoring system (CGMS), in 31 patients stratified according to the presence of type 2 diabetes and PD. Materials and Methods. The study included 31 patients (11 type 2 diabetic PD patients, 9 non diabetic PD patients and 11 type 2 diabetic patients without PD). Glycemic variability was assessed on CGM readings by: Mean Amplitude of Glycemic Excursion (MAGE), Mean of Daily Differences (MODD), Fractal Dimensions (FD), Mean Interstitial Glucose (MIG), Area Under glycemia Curve (AUC), M100, % time with glucose >180/<70 mg/dl. Results. The PD diabetic patients presented AUC, MIG and inter-day glycemic variability (MODD) significantly higher than diabetic patients without PD. In PD patients, the type of dialysis fluid in the nocturnal exchange and peritoneal membrane status did not significantly influence glycemic variability. Conclusions. CGMS is more useful than HbA1c in quantifying the metabolic imbalance of PD patients. PD induces inter-day glycemic variability and poor glycemic control, thus being a potential risk factor for chronic complications progression in diabetic patients.


2021 ◽  
pp. 193229682199206
Author(s):  
Bruno Vergès ◽  
Elise Pignol ◽  
Alexia Rouland ◽  
Benjamin Bouillet ◽  
Sabine Baillot-Rudoni ◽  
...  

Mean amplitude of glucose excursion (MAGE) is considered as the “gold standard” for assessing the short-term within-day glycemic variability (GV), which is an important component of overall glycemic control. A 14-day continuous glucose monitoring system is now widely used and allows easier assessment of GV. However, it is still unknown whether MAGE, usually calculated on a 48-hour period is identical whatever the time during the 14-day lifespan of the sensor and whether a longer time period might give additional information. We evaluated in 68 patients with type 1 diabetes, MAGE during three 2-day periods (day1-day3; day6-day8; day11-day13) and during periods of 3 days and 4 days. MAGE calculated at the three 2-day periods were identical and not different from MAGE of the 3-day or 4-day periods.


Sign in / Sign up

Export Citation Format

Share Document